Caliber Imaging & Diagnostics, Inc. (LCDX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.45: the stock has moved about 55% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCaliber Imaging & Diagnostics, Inc. (LCDX) trades at $0.0001. Caliber Imaging & Diagnostics, Inc. is a U.S.-based medical technology firm specializing in advanced imaging solutions for cellular-resolution tissue visualization. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for LCDX: LCDX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Caliber Imaging & Diagnostics, Inc. (LCDX) Healthcare & Pipeline Overview
Caliber Imaging & Diagnostics, Inc. is a U.S.-based medical technology firm specializing in advanced imaging solutions for cellular-resolution tissue visualization. The company develops, manufactures, and markets systems like VivaScope 1500 and VivaScope 3000, alongside VivaScan software and VivaNet telepathology, serving medical practitioners and scientists in diagnostic applications.
What Is the Investment Thesis for LCDX?
Caliber Imaging & Diagnostics, Inc. operates in the medical device sector, leveraging its advanced imaging solutions for cellular-resolution tissue visualization as a core value driver. The company's product suite, including the VivaScope 1500, VivaScope 3000, VivaScan, and VivaNet, addresses a specific need for high-fidelity, non-invasive diagnostics. However, the company faces significant financial challenges, evidenced by a negative profit margin of -164.0% and a market capitalization of $0.00B, indicating a micro-cap status and substantial unprofitability. Its beta of 0.45 suggests lower volatility relative to the broader market, yet this must be weighed against its operational and financial profile. As an 'OTC Other' listed stock, LCDX carries inherent risks of limited liquidity and regulatory oversight, requiring investors to closely monitor its ability to secure funding and navigate the complex medical device regulatory landscape. Potential growth catalysts include increased adoption of its specialized imaging technology, expansion into new diagnostic applications, and successful strategic partnerships to bolster its market presence and financial stability.
Based on FMP financials and quantitative analysis
LCDX Key Highlights
Market Capitalization: $0.00B, reflecting a micro-cap status and extremely limited valuation.
- Profit Margin: -164.0%, indicating significant operational losses relative to revenue.
- Gross Margin: 19.6%, suggesting challenges in cost of goods sold relative to its pricing strategy.
- Beta: 0.45, indicating lower price volatility compared to the overall market.
- Employee Count: 28 employees, highlighting a relatively small operational scale for a medical technology firm.
Who Are LCDX's Competitors?
LCDX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $0.76 | -9.01% | 30 5-pillar | |
| NVNO enVVeno Medical Corporation | $8.01 | -1.11% | $5.63M | 30 5-pillar |
| BDMD Baird Medical Investment Holdings Limited | $0.74 | -1.09% | $31.4M | — |
| SNWV SANUWAVE Health, Inc. | $4.70 | -2.49% | $41.5M | 36 5-pillar |
| SRTS Sensus Healthcare, Inc. | $2.92 | -2.01% | $48.1M | 31 5-pillar |
| HYPD Hyperion DeFi, Inc. | $3.89 | +4.29% | $56.5M | 36 5-pillar |
| LNSR LENSAR, Inc. | $6.67 | -1.19% | $81.9M | 45 5-pillar |
| APYX Apyx Medical Corporation | $2.60 | +1.96% | $107M | 33 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LCDX's Key Strengths?
Proprietary advanced imaging technology for cellular-resolution tissue visualization.
- Specialized product portfolio including VivaScope 1500, VivaScope 3000, VivaScan, and VivaNet.
- Established operational history since 1991 in the medical technology sector.
- Focus on non-invasive diagnostic tools for living tissue.
What Are LCDX's Weaknesses?
Significant unprofitability with a -164.0% profit margin.
- Limited market capitalization ($0.00B) indicating micro-cap status.
- Small operational scale with only 28 employees.
- OTC Other listing, implying limited liquidity and disclosure requirements.
What Are the Key Risks for LCDX?
Financial-distress signal — its Altman Z-Score of -44.20 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Significant financial losses and negative profit margin (-164.0%), posing sustainability challenges.
- Limited liquidity and transparency due to its 'OTC Other' listing and small market capitalization.
- Inability to secure sufficient funding for continued research, development, and market penetration.
- Intense competition from larger, well-capitalized medical device companies with broader product portfolios.
- Regulatory hurdles and the need for continuous compliance in the evolving medical device landscape.
What Threats Does LCDX Face?
- Intense competition from larger, better-funded medical imaging companies.
- Regulatory hurdles and lengthy approval processes for medical devices.
- Challenges in securing adequate funding for R&D and market expansion.
- Risk of technological obsolescence from rapidly evolving imaging modalities.
What Are LCDX's Competitive Advantages?
- Proprietary cellular-resolution imaging technology, specifically reflectance confocal microscopy, for in vivo tissue visualization.
- Specialized product suite tailored for precise diagnostic applications in living tissue, offering unique capabilities.
- Integrated hardware and software ecosystem (VivaScope, VivaScan, VivaNet) providing a comprehensive solution.
- Established operational history since 1991, indicating deep expertise and experience in advanced medical imaging.
What Does LCDX Do?
Caliber Imaging & Diagnostics, Inc. is a U.S.-based medical technology firm dedicated to the development, manufacturing, and marketing of advanced imaging solutions that enable the visualization of living tissue at a cellular resolution. The company was initially established in 1991 under the name Lucid, Inc., marking its entry into the medical imaging landscape. Over two decades later, in August 2012, the company underwent a rebranding to its current identity, Caliber Imaging & Diagnostics, Inc., and maintains its headquarters in Andover, Massachusetts. Its core product portfolio is designed to empower medical practitioners and scientists with high-fidelity diagnostic tools. Central to its offerings is the VivaScope 1500, a sophisticated reflectance confocal imaging system. This device allows for the capture of detailed confocal images, providing an unprecedented view into the cellular architecture of living tissue, which is crucial for precise diagnostics and research. Complementing this stationary system, the company also provides the VivaScope 3000, a handheld in vivo reflectance confocal microscope specifically tailored for dermatological imaging. This portable solution offers flexibility and convenience for skin examinations, enabling on-the-spot cellular-level analysis. Beyond hardware, Caliber Imaging & Diagnostics extends its capabilities through specialized software. VivaScan is designed to streamline various operational aspects, including patient scheduling, facilitating multi-lesion imaging during appointments, and assisting with comprehensive image review and reporting. Furthermore, the firm supplies VivaNet, a sophisticated digital telepathology system that supports remote diagnostic capabilities, enhancing collaboration and access to expert analysis. The company's focus on non-invasive, high-resolution imaging positions it within the innovative segment of the medical device sector, addressing critical diagnostic needs.
What Products and Services Does LCDX Offer?
- Develops advanced imaging solutions for cellular-resolution tissue visualization.
- Manufactures the VivaScope 1500, a reflectance confocal imaging system for detailed cellular architecture.
- Markets the VivaScope 3000, a handheld in vivo reflectance confocal microscope tailored for dermatological imaging.
- Provides VivaScan software for streamlined patient scheduling, multi-lesion imaging, and image review and reporting.
- Offers VivaNet, a sophisticated digital telepathology system for remote diagnostic capabilities.
- Enables medical practitioners and scientists to capture detailed confocal images of living tissue.
- Focuses on non-invasive diagnostic tools within the medical device sector.
How Does LCDX Make Money?
- Sells advanced imaging hardware, including the VivaScope 1500 and VivaScope 3000, to medical facilities and research institutions.
- Generates revenue from software licenses and subscriptions for its VivaScan and VivaNet platforms.
- Provides ongoing maintenance, service, and technical support for its installed base of imaging systems.
- Potentially derives revenue from specialized accessories or consumables related to its imaging platforms.
What Industry Does LCDX Operate In?
Caliber Imaging & Diagnostics, Inc. is positioned within the dynamic medical device sector, specifically focusing on advanced diagnostic imaging technologies. The industry is characterized by a continuous drive towards non-invasive, high-resolution imaging solutions that enable earlier and more accurate disease detection. Market trends indicate a growing demand for specialized imaging tools, particularly in areas like dermatology and pathology, where cellular-level detail is paramount. LCDX differentiates itself by specializing in reflectance confocal imaging, providing cellular-resolution visualization of living tissue, which sets it apart from broader imaging modalities. The competitive landscape includes both large, diversified medical technology companies and smaller, innovative firms focused on niche imaging solutions. Caliber Imaging & Diagnostics aims to carve out its market share by offering highly specialized hardware and integrated software solutions that cater to the precise diagnostic needs of medical practitioners and scientists.
Who Are LCDX's Key Customers?
- Medical practitioners, including dermatologists and pathologists, seeking advanced diagnostic tools.
- Scientists and researchers in academic, pharmaceutical, and private institutions utilizing cellular imaging.
- Hospitals and specialized clinics requiring high-resolution, non-invasive diagnostic capabilities.
- Telemedicine providers and pathology labs leveraging digital telepathology systems.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Insider Activity
12 transactions · 8 purchases, 0 sales, 4 other transactions · 1 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Key Financial Metrics
Return on equity for Caliber Imaging & Diagnostics, Inc. stands at 54.2%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.31 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Caliber Imaging & Diagnostics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -44.20 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Caliber Imaging & Diagnostics, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Andover, US. The company is led by CEO L. Michael Hone. LCDX has traded publicly since 2012.
LCDX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
LCDX Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
LCDX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for LCDX.
Price Targets
Wall Street price target analysis for LCDX.
LCDX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for LCDX; grades run from A+ (80-100) to F (below 30).
Leadership: L. Michael Hone
Chief Executive Officer
L. Michael Hone serves as the Chief Executive Officer of Caliber Imaging & Diagnostics, Inc., overseeing its operations and strategic direction. With a focus on advancing medical technology, Mr. Hone is responsible for managing the company's 28 employees and guiding its efforts in developing, manufacturing, and marketing advanced imaging solutions. His leadership is central to the company's mission of providing cellular-resolution tissue visualization tools to medical practitioners and scientists.
Track Record: Under Mr. Hone's leadership, Caliber Imaging & Diagnostics, Inc. continues to focus on its core product lines, including the VivaScope 1500, VivaScope 3000, VivaScan, and VivaNet systems. His tenure has seen the company maintain its specialization in reflectance confocal imaging for diagnostic applications. Key achievements and strategic decisions beyond these operational continuities are not detailed in the provided information.
LCDX OTC Market Information
Caliber Imaging & Diagnostics, Inc. trades on the 'OTC Other' tier of the OTC Markets. This tier is for companies that do not meet the disclosure requirements for OTCQX or OTCQB, or choose not to provide current information. Unlike exchanges such as the NYSE or NASDAQ, which have stringent listing standards for financial health, corporate governance, and minimum share prices, 'OTC Other' has minimal requirements. This often results in less transparency and higher risk for investors compared to exchange-listed or even higher-tier OTC stocks.
- OTC Tier: OTC Other
- Limited public disclosure and transparency due to 'OTC Other' classification.
- Extremely low trading volume and wide bid-ask spreads, leading to illiquidity.
- Difficulty in securing capital and attracting institutional investment.
- Increased susceptibility to market manipulation and price volatility.
- Potential for delisting or further restrictions if disclosure status remains 'Unknown'.
- Verify any available financial statements and corporate filings directly from the company or OTC Markets.
- Research the company's operational status, product sales, and customer base beyond public filings.
- Assess the competitive landscape and the company's market position within the medical device sector.
- Investigate any recent news, press releases, or investor relations updates from the company.
- Evaluate the management team's experience and track record, seeking information beyond basic profiles.
- Understand the regulatory environment for their medical devices and any pending approvals.
- Consider the potential for dilution from future capital raises.
- Established company history, founded as Lucid, Inc. in 1991.
- Specific product lines (VivaScope 1500, VivaScope 3000, VivaScan, VivaNet) with defined applications.
- Headquartered in Andover, Massachusetts, indicating a physical operational base.
- Operates in a specialized segment of the medical technology industry.
What Investors Ask About Caliber Imaging & Diagnostics, Inc. (LCDX) — Healthcare
What revenue streams does Caliber Imaging & Diagnostics, Inc. have in healthcare?
Caliber Imaging & Diagnostics, Inc. primarily generates revenue through the sale of its advanced medical imaging hardware and associated software solutions.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Specific market sizes and timelines for growth opportunities are inferred based on general industry trends due to lack of explicit data.
- Detailed CEO background and track record beyond basic information are not available in the provided sources.
- The 'disclosureLevel' for OTC analysis is 'Unknown' as stated in the source data.